A Phase 3 interventional study of Levetiracetam in Epilepsy, Partial, sponsored by UCB Pharma. Completed. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-12-03.
Sponsored by UCB Pharma · Phase 3 and Interventional
clinical efficacy and safety of Levetiracetam as add-on therapy in adult Chinese subjects with partial seizures.
1,805 studies on the registry are indexed under Epilepsy; 417 are open to participants now.
This study's enrollment of 192 is above the median of 50 across 1,206 interventional studies indexed under Epilepsy.
Browse Epilepsy studies →UCB Pharma is the lead sponsor of 238 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The partial onset (type I) seizure frequency reduction per week over the 16-week treatment period (titration and maintenance)
Seizure freedom ;
The partial onset (type I) seizure reduction response rate ;
Safety and tolerability
No study locations are listed for this record.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
UCB Pharma